Navigation Links
External beam RT for early-stage breast cancer does not increase mortality risks
Date:9/24/2013

Atlanta, September 24, 2013Early-stage breast cancer patients who receive external beam therapy (XRT) are not at higher risk for serious long-term side effects in the chest area, including increase in deaths from cardiac disease and secondary malignancies, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

The study utilized patient information from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database. It evaluated women identified as having primary Stage T1aN0 breast cancer (tumor of 5mm or less that has not spread to the lymph nodes), who received surgery, with or without post-operative radiation therapy, between 1990 and 1997. The analysis was done to determine if XRT was associated with increased mortality due to breast cancer, secondary cancer in the chest area or cardiac conditions for these patients; only patients with breast cancer (BC) identified as the first malignancy were included. The women had a median age of 55-59 and were divided into two groups: 2,397 who received XRT after surgery, and 2,988 who did not receive XRT after surgery.

Cause of death (COD) codes were used to identify cardiac mortality, breast cancer mortality, and deaths from secondary chest cancers in order to assess overall survival (OS), breast cancer survival (BCS), second-tumor specific survival and cardiac-cause specific survival (CCS), and then compared between the XRT and non-XRT groups. The incidence of mortality was compared between the XRT and non-XRT groups utilizing the Chi-Square test; and, the relative risk (RR) and associated 95 percent confidence interval (CI) were calculated. Kaplan-Meier survival analysis and log-rank test were performed to assess OS, BCS, second-tumor specific survival and CCS.

At 10 years post-treatment, OS rates were 91.6 percent for the XRT patients and 87 percent for the non-XRT group; BCS rates were 97 percent for the XRT patients and 95.7 percent for the non-XRT group; and CCS was 96.7 percent for the XRT patients and 92.7 percent for the non-XRT group.

Analysis of the data further demonstrates that, with a median follow up of 14 years, there was no statistically significant difference in deaths from subsequent non-breast cancers in the chest area, the majority of which were lung cancers. The number of deaths from cardiac causes was not significantly higher for those patients treated with XRT for left-sided breast cancer, compared to those with right-sided breast cancer among the patient sample and time period reviewed. More women from the non-XRT group died from all causes, including cardiac causes, suggesting that those patients had worse general health conditions than the women who received radiation therapy.

"Breast conserving therapy, consisting of lumpectomy and XRT, has been an excellent approach to early breast cancer treatment, offering equivalent disease control and better cosmetic results compared to mastectomy as demonstrated by multiple randomized controlled trials in the past," said Jason Ye, MD, the study's presenting author and a second-year resident in radiation oncology at Weill Cornell Medical College in New York City. "Our study's results suggest that serious long-term side effects of radiation therapy, such as increase in deaths from cardiac disease and secondary malignancies, are rare. Radiation therapy is an integral part of early stage breast cancer treatment for those who choose to have a lumpectomy instead of a mastectomy, with its benefits likely far outweighing the potential risks in majority of the cases. The field of radiation oncology is rapidly changing, with new technology constantly being introduced that may reduce these risks further. Continued long term follow up and additional studies are needed to monitor for potential long term side effects."


'/>"/>

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. AED.com Supports Automated External Defibrillator (AED) Legislation in Schools in US and UK
2. North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com
3. Automated External Defibrillator Market to Reach $930 Million by 2017 - New Report by MarketsandMarkets
4. AED.com Now Offers Automated External Defibrillator (AED) Sports Packages
5. San Jose CPR Certification Now Sells AEDs (Automated External Defibrillators) and Teaches CPR/AED Certification Training Classes in San Jose, CA
6. Joan Bowman, VP External Affair, to Speak at Mid-Continental States Association of Food and Drug Officials (MCAFDO)
7. Gammapod developed at University of Maryland School of Medicine targets early-stage breast cancer
8. NIH-developed candidate dengue vaccine shows promise in early-stage trial
9. Radiation treatment after surgery improves survival for elderly women with early-stage breast cancer
10. Many options, good outcomes, for early-stage follicular lymphoma
11. Study: Majority of older, early-stage breast cancer patients benefit from radiation after lumpectomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The aging population and ... long term care. With that, says Patrick Loughney, president of Longtree & ... in long term care environments. His company, which offers prep courses and workshops ...
(Date:2/12/2016)... ... February 12, 2016 , ... Dignity Health named Dr. Scott Bingham the ... The new facility is licensed under Dignity Health Arizona General Hospital , ... excellent leader and will ensure our new freestanding emergency room delivers the highest quality ...
(Date:2/11/2016)... ... 2016 , ... Student-doctors from Western University of Health Sciences’ ... February 9, taking one of the final steps in their medical school career. ... the country. Of the 103 student-doctors who comprise the College of Osteopathic Medicine ...
(Date:2/11/2016)... , ... February 11, 2016 , ... Image One ... to a new market, and it’s the buildings of Nashville that will benefit. , ... I needed to relocate to Nashville, there was no question that I would bring ...
(Date:2/11/2016)... ... February 11, 2016 , ... Thermi™, a world leader in ... announce the promotions of Allison Kelly to executive vice president of the company’s ... president of North American capital sales, and Wendy Oseas to vice president of ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12 2016  OMS Supply, a ... and medical practitioners, announced today the recent launching of ... visitors a variety of features that enhance the user ... surgery supplies. --> ... a fairly new company that started in early 2016, ...
(Date:2/12/2016)... 12 februari 2016 AAIPharma Services ... leverancier van productie en ontwikkeling op maat ... vandaag een uitbreiding aan van steriele vul- ... in Charleston, SC . ... meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/12/2016)... 2016  Apellis Pharmaceuticals, Inc., today announced ... Series D preferred stock financing, co-led by ... Group and venBio Global Strategic Fund, joining ... Investment, and Epidarex Capital. The proceeds of the ... clinical trials in the Company,s ongoing complement ...
Breaking Medicine Technology: